60 Degrees Pharmaceuticals is engaged in the development and commercialization of medicines and therapies for infectious diseases.

60 Degrees Pharmaceuticals

AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

Carl Hansen

Kevin Heyries

Véronique Lecault

AbCellera Biologics Inc.

BayernLB is a bank that provides financial services, including sustainable financing options self-described as supporting sustainable transformation, ESG consulting, and real estate services.

Metric
Company Name	60	AbCellera Biologics Inc.	BayernLB
Symbol		ABCL
MSH ID	COM:60DEGREESPHARMA	COM:ABCELLERA	DE:BAYERNLB
Market	PRIVATE	STOCKS	PRIVATE
Sector	Healthcare & Health Services	Healthcare	Financial Services & Finance
Industry	Pharmaceuticals	Biotechnology	Banking
Country	US	CA	DE
Stage
Employee Count		586
Website	60degreespharma.com	abcellera.com	bayernlb.de
LinkedIn
Founders

Metric
Market Cap		823.35M
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue		38.02M
Revenue (LTM)
Revenue (NTM)
Gross Profit		7.13M
EBITDA		-192.16M
Operating Income		-237.21M
Net Income		-146.40M
EPS		-0.51
Diluted EPS		-0.51
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin		0.30
Operating Profit Margin		-6.15
EBITDA Margin		-5.05
Net Profit Margin		-3.85
Return on Equity		-0.12
Return on Assets		-0.10
Return on Capital Employed		-0.17

60DE

COM:60DEGREESPHARMA

60 Degrees Pharmaceuticals

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio		-11.06
P/B Ratio		1.21
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio		35.65
EV Multiple		-4.01

Metric
Days Sales Outstanding		546.74
Days Payables Outstanding		4.09K
Days Inventory Outstanding		8.82
Operating Cycle		747.59
Cash Conversion Cycle		589.35
Asset Turnover		0.05

Metric
Operating Cash Flow		-43.88M
Free Cash Flow		-121.38M
Cash Flow to Debt		-0.56
Operating Cash Flow/Sales		-1.15
Free Cash Flow Yield		-0.05

Metric
Cash & Equivalents		133.32M
Accounts Receivable		-45.93M
Inventory		1.11M
Goodwill		47.81M
Debt to Capitalization		0.06
Debt to Assets		0.05
Current Ratio		8.34
Quick Ratio		10.96

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue		1.21
R&D to Revenue		3.08
SG&A to Revenue		1.15